819 TTT
Carbyon
Carbyon is a climate-tech startup focused on capturing carbon dioxide directly from the air using its proprietary fast-swing thin-film technology. The company aims to make direct ...
More informationInvesting in tomorrow's success
819 Capital Partners is a dynamic and forward-thinking investment firm specializing in venture capital, private equity, and corporate finance. Our mission is to drive innovation, growth and value creation for our partners through a diverse portfolio of investments, positively impacting key sectors.
Expertise to realise growth and maximise value
€85M+
Total AUM
Venture, Growth, Control, Buy-and-build
Transaction type
42
Portfolio companies
€500M+
Revenues active investments
1,000+
Portfolio employees
819 TTT
819 TTT
XS Innovations
XS Innovations is a medical‑device startup (spin‑out of Leiden University Medical Center & Delft University of Technology) that develops an implantable vascular access solution for patients ...
More information
819 Evergreen Fund I
I-Med Technology
I-Med Technology develops and markets advanced head-mounted 3D imaging systems that provide real-time support, enhancing precision and efficiency in medical and dental procedures. The company is ...
More information
819 TTT
Relement
Relement is a spin‑off from TNO / Biorizon, specializing in converting non‑food biomass residues into high‑quality, bio‑based aromatic chemical building blocks. Their first product — “bio‑MPA” ...
More information
819 Evergreen Fund I
Sencure
Sencure develops chips that helps you measure electrophysiological parameters on the human body in innovative ways.
More information
819 TTT
Predica Diagnostics
Predica Diagnostics is a medical‑diagnostics startup (a spin‑off from RadboudUMC) that develops and markets assays for oncology and women’s health using their proprietary targeted RNA‑sequencing technology ...
More information
819 TTT
Powall
Powall uses nanotechnology to enhance the performance of powders through ultra-thin surface coatings. Their gas-phase deposition technology enables precise modification of powder materials used in batteries, ...
More information
819 TTT
MicroAlign
MicroAlign is a deep-tech spin-off from Eindhoven University of Technology focused on ultra-precise alignment of optical fibers to photonic chips. The company produces fiber arrays with ...
More information
819 Evergreen Fund I
CiMaas
CiMaas, a biotech company based in Maastricht, develops Natural Killer (NK) cell therapies for cancer treatment. Founded as a spin-off from Maastricht University, the company focuses ...
More information
819 Evergreen Fund I
RiverD
RiverD is a Dutch high-tech company developing and manufacturing advanced instruments for non-invasive molecular analysis of human skin and tissue using Raman spectroscopy. Its skin analysis ...
More informationOur news
March 6, 2026
819 Capital Partners acquires key assets of Lead Pharma, enabling continuation of operations
Deventer, 6 March 2026 - 819 Capital Partners has acquired the key assets of Lead Pharma, thereby realizing a continuation based on the company’s patent portfolio and associated research programs. The transaction includes intellectual property rights, research data, and selected development programs. Lead Pharma develops innovative small-molecule medicines for the treatment of cancer and autoimmune diseases. Over the past years, the company built a strong research platform and multiple drug candidates, collaborating with international pharmaceutical companies...
Continue reading
February 10, 2026
819 Capital Partners acquires Chalet.nl
Deventer, 10 February 2026 – 819 Capital Partners announces the acquisition of Chalet.nl, a well-established Dutch touroperator that has been a leading authority in winter sports holidays for more than 25 years. Chalet.nl specializes in the organization and rental of chalets and apartments in leading winter sports destinations across France, Austria, Switzerland and Italy. The company has built a strong online presence and is known for its reliable service, personal approach, and deep expertise in...
Continue reading